Sat, Dec 27, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

A third of surveyed insurers say they will increase allocation to alternatives in the wake of Solvency II

Wednesday, March 07, 2012

Benedicte Gravrand, Opalesque Geneva: As European insurers are scrambling ahead of the implementation of Solvency II, a new EU directive, BlackRock commissioned a report on the effect of Solvency II on asset allocation and investment strategy, which was written by the Economist Intelligence Unit last month.

The report found, among other things, there is a degree of discrepancy between market perception and what insurers think, "particularly in relation to use of alternatives and their levels of preparedness for Solvency II governance and disclosure requirements." It also found that alternatives such as hedge funds and private equity will benefit from the new requirements.

Solvency II is a fundamental review of the capital adequacy regime for the European insurance industry, which means that all EU/EEA countries will be united by a single set of rules governing what constitutes an acceptable level of insurer creditworthiness. This EU Directive should come into effect on 1 January 2014.

There are uncertainties as to whether the date of implementation will be pushed back a year, says the BlackRock report (Balancing risk, return and capital requirements),......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its